Based on such a body of nonclinical and clinical evidences, we think that CBF measurement is enough for outcome measure in the rat stroke model since the purpose of the present study is to assess whether we can minimize the gap in the effective dose of rt-PA between rats and humans by using the tPA Tg rats. The gene discussed is PLAT; the disease is stroke disorder.